Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
NBIX
Stock Latest News
Company Announcements
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
1d ago
NBIX
Premium
The Fly
Neurocrine announces new data from a clinician survey in Ingrezza
2d ago
NBIX
Premium
Company Announcements
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
2d ago
8K
NBIX
Premium
The Fly
Neurocrine completes acquisition of Soleno Therapeutics
3d ago
NBIX
SLNO
Premium
The Fly
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
5d ago
AARD
NBIX
Premium
The Fly
Neurocrine price target raised to $185 from $177 at JPMorgan
13d ago
NBIX
Premium
The Fly
Neurocrine price target raised to $155 from $140 at Truist
13d ago
NBIX
Premium
The Fly
Neurocrine price target raised to $155 from $150 at Deutsche Bank
13d ago
NBIX
Premium
The Fly
Neurocrine treatment of Friedreich ataxia granted orphan designation
13d ago
NBIX
Premium
The Fly
Neurocrine price target raised to $246 from $242 at Citi
14d ago
NBIX
Premium
The Fly
Neurocrine price target raised to $207 from $190 at Piper Sandler
14d ago
NBIX
SLNO
Premium
The Fly
Neurocrine price target raised to $191 from $185 at Morgan Stanley
14d ago
NBIX
Premium
The Fly
Neurocrine price target raised to $230 from $220 at Oppenheimer
14d ago
NBIX
Premium
The Fly
Neurocrine price target raised to $155 from $140 at Truist
14d ago
NBIX
Premium
Ratings
Evan Seigerman Maintains Hold on Neurocrine as Strong Commercial Execution Drives Price Target Increase to $144 Amid Strategic Uncertainty
14d ago
NBIX
Premium
Ratings
Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks
15d ago
NBIX
Premium
Ratings
Neurocrine Remains Top Pick on Durable Multi‑Year Growth Outlook; Buy Rating Reiterated with Unchanged $200 Price Target
15d ago
NBIX
Premium
Company Announcements
Neurocrine Biosciences Delivers Record Quarter, Eyes 2027
15d ago
NBIX
Premium
Ratings
Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand
15d ago
NBIX
Premium
Ratings
NBIX: Strong Crenessity and Ingrezza Outperformance, Robust 2026 Outlook and Pipeline Catalysts Underpin Buy Rating
15d ago
NBIX
Premium
The Fly
Neurocrine reports Q1 adjusted EPS $1.94, consensus $1.70
15d ago
NBIX
Premium
The Fly
Neurocrine backs FY26 Ingrezza net product sales $2.7B-$2.8B
15d ago
NBIX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
